Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).
It is very uncertain whether docetaxel changes time to progression compared with non‐docetaxel‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes time to progression compared with 5‐FU‐containing regimens (very low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).